Richard J. Nowak, MD, is director of the Myasthenia Gravis Clinic, director of Clinical & Translational Neuromuscular Research (CTNR), and associate professor of neurology at Yale School of Medicine.

The treatment pipeline for generalized myasthenia gravis (gMG) continues to be active, a consequence of the ongoing progress in knowledge that led to approval of six new drugs for the disease. In ...

A month ago, argenx announced that the FDA had accepted its application to expand Vyvgart to those with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG), for ...

Myasthenia gravis is a lifelong (chronic) autoimmune condition, which means that the body’s immune system attacks its own healthy cells. Most people with generalized myasthenia gravis (gMG) have ...

New guidelines and advocacy enhance myasthenia gravis treatment access, promoting proactive management and improved insurance coverage for diverse patient populations. There are key systemic factors ...

SAN FRANCISCO — Efgartigimod (Vyvgart), a neonatal Fc receptor (FcRn) antagonist, significantly improved symptoms in patients with anti-acetylcholine receptor antibody (AChR-Ab)-negative generalized ...

Efgartigimod alfa–hyaluronidase significantly improves ocular symptoms in adults with ocular myasthenia gravis, according to phase 3 trial data.

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. An mRNA‑based CAR T therapy called Descartes‑08 is giving many people with myasthenia gravis ...

Experts discuss personalized myasthenia gravis treatment, emphasizing patient education and engagement for optimal care and advocacy in managing this variable disease. Personalizing treatment for ...

Nicholas J. Silvestri, MD, recounts how the 2025 American Academy of Neurology meeting was an exciting and energizing event, particularly in the realm of myasthenia gravis (MG), where numerous new ...